EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Waverley Pharma's enterprise value is C$2.46 Mil.
Waverley Pharma's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was C$0.54 Mil. Therefore, Waverley Pharma's EV-to-Revenue for today is 4.52.
The historical rank and industry rank for Waverley Pharma's EV-to-Revenue or its related term are showing as below:
TSXV:WAVE'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.88 Med: 3.44 Max: 54.61
Current: 4.52
During the past 7 years, the highest EV-to-Revenue of Waverley Pharma was 54.61. The lowest was 0.88. And the median was 3.44.
TSXV:WAVE's EV-to-Revenue is ranked better than 63.05% of 1031
companies
in the Biotechnology industry
Industry Median: 7.91
vs TSXV:WAVE: 4.52
As of today (2024-05-02), Waverley Pharma's stock price is C$0.025.
Waverley Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was C$0.01. Therefore, Waverley Pharma's PS Ratio for today is 2.50.
Waverley Pharma EV-to-Revenue Historical Data
The historical data trend for Waverley Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Waverley Pharma's EV-to-Revenue
For the Biotechnology subindustry, Waverley Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waverley Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Waverley Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Waverley Pharma's EV-to-Revenue falls into.
Waverley Pharma's current Enterprise Value is C$2.46 Mil.
Waverley Pharma's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waverley Pharma's share price for today is C$0.025.
Waverley Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waverley Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Waverley Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:WAVE has been successfully added to your 